Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 56,195 |
|
|||||
| News | - | ||||||
| Day High | 1.50 | Low High |
|||||
| Day Low | 1.42 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Scynexis Inc | SCYX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.05 | -3.33% | 1.45 | 12:16:15 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.48 | 1.42 | 1.50 | 1.50 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 235 | 56,195 | $ 1.46 | $ 81,977 | - | 1.35 - 3.87 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:16:15 | 100 | $ 1.45 | USD |
Scynexis Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 55.07M | 37.21M | - | 140.14M | 67.04M | 1.80 | 0.82 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Scynexis News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SCYX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.43 | 1.6058 | 1.39 | 1.48 | 104,580 | 0.02 | 1.40% |
| 1 Month | 1.42 | 1.86 | 1.37 | 1.57 | 203,439 | 0.03 | 2.11% |
| 3 Months | 2.10 | 2.17 | 1.35 | 1.64 | 204,711 | -0.65 | -30.95% |
| 6 Months | 1.66 | 2.37 | 1.35 | 1.74 | 209,331 | -0.21 | -12.65% |
| 1 Year | 3.00 | 3.87 | 1.35 | 2.39 | 302,781 | -1.55 | -51.67% |
| 3 Years | 7.44 | 11.30 | 1.15 | 3.88 | 404,619 | -5.99 | -80.51% |
| 5 Years | 1.70 | 11.30 | 0.50 | 3.16 | 469,057 | -0.25 | -14.71% |
Scynexis Description
| SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains. |
